Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Check Point's Recovery Delayed as Customer Deals Slip Into 2027, RBC Says

Check Point's Recovery Delayed as Customer Deals Slip Into 2027, RBC Says

MT newswireMT newswire2026/11/03 15:29
11:29 AM EST, 11/03/2026 (MT Newswires) -- Check Point Software Technologies (CHKP) faces a longer-than-expected recovery as customer deal delays and weaker product sales continue to pressure growth, RBC Capital Markets said Monday in a report. The cybersecurity company reported mixed Q3 results, with revenue, product revenue and billings missing expectations, the report said. RBC said product revenue was hurt by weaker firewall refresh activity and by roughly $20 million to $30 million of customer deals that were pushed into 2027. Management expects product revenue to decline again in Q4 before returning to growth in Q2 2027, while the benefits of earlier go-to-market changes are taking longer than anticipated to materialize, the report said. RBC said it expects Check Point will need multiple quarters to show sustained improvement and slow market-share losses. RBC said several faster-growing businesses remain bright spots, including email security, exposure-management and AI security offerings. Subscription revenue growth should improve in H1 2027, helped by easing headwinds, higher pricing and contributions from newer security offerings, the report said. RBC raised its price target on Check Point stock to $140 from $135 and maintained its sector-perform rating. Price: 139.53, Change: -1.97, Percent Change: -1.39
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss